Clinical Trial Update: A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study (DYNASTY-Breast02) comparing DB-1303/BNT323 against investigator's choice chemotherapy in HER2-low, hormone…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BNT323
• DB-1303

Snippet

Sponsor: DualityBio Inc. | Conditions: Metastatic Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING